


Claims

1. A compound of formula (I):



5

wherein:

$R^1$  represents substituted or unsubstituted heteroaryl;

$Y$  represents  $-(CR_{na}R_{nb})_n-$ ;

10  $R_{na}$  and  $R_{nb}$  are each independently hydrogen or  $C_{1-6}$ alkyl;

$n$  is an integer from 1 to 5;

$R^2$  represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;

$R^3$  represents hydrogen or  $C_{1-6}$ alkyl;

15 and salts and solvates thereof;

with the provisos that;

$R^1$  is not oxazolyl;

$R^1$  is not substituted by phenyl, and;

the following compounds are excluded;

20 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide;

N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-thien-3-ylacetamide;

N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(5-methyl-1-phenyl-1H-pyrazol-4-yl)acetamide;

25 2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]acetamide;

N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;

N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(2-furyl)acetamide;

30 2-(3-acetyl-1-benzothien-4-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]acetamide trifluoroacetate;

2-(5-bromopyridin-3-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]acetamide compound with formic acid (1:1);

N-[[[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(2-furyl)acetamide;

- 2-(4-bromo-1H-imidazol-1-yl)-N-([4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]acetamide;  
 N-([4-(3,4-difluorobenzyl)morpholin-2-yl)methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;  
 5 N-([4-(4-fluorobenzyl)morpholin-2-yl)methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;  
 N-([4-(2,3-dichlorobenzyl)morpholin-2-yl)methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;  
 N-([4-(5-chlorothien-2-yl)methyl)morpholin-2-yl)methyl]-2-(2-pyrazin-2-yl-1,3-  
 10 -thiazol-4-yl)acetamide;  
 N-([4-(3-chlorobenzyl)morpholin-2-yl)methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;  
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]-2-(5-methyl-2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;  
 15 methyl 2-[2-([4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]amino)-2-oxoethyl]-2H-1,2,3-benzotriazole-5-carboxylate;  
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]-2-(1H-pyrrolo[2,3-b]pyridin-1-yl)acetamide;  
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]-2-(5-pyridin-2-yl-2H-tetraazol-2-yl)acetamide;  
 20 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]-2-(5-pyridin-3-yl-2H-tetraazol-2-yl)acetamide;  
 methyl 1-[2-([4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]amino)-2-oxoethyl]-1H-1,2,3-benzotriazole-5-carboxylate compound with methyl 1-[2-([4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]amino)-2-oxoethyl]-1H-1,2,3-benzotriazole-6-carboxylate (1:1);  
 25 N-([(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]-2-(5-methyl-2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide, and;  
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl)methyl]-2-(2,3-dimethylquinoxalin-6-yl)acetamide.  
 30



2. A compound of formula (I) according to claim 1 wherein R<sup>1</sup> is unsubstituted or substituted imidazolyl, unsubstituted or substituted triazolyl, unsubstituted or substituted triazolyl, unsubstituted or substituted oxadiazolyl, unsubstituted or substituted thiazolyl, unsubstituted or substituted thiophenyl, unsubstituted or substituted isoxadiazolyl, unsubstituted or substituted isoxathiazolyl, unsubstituted or substituted pyridinyl, unsubstituted or substituted furanyl, unsubstituted or substituted isoxazolyl, unsubstituted or substituted tetrazolyl and unsubstituted or substituted pyrazolyl.  
 35  
 40

3. A compound of formula (I) according to claim 1 or claim 2 wherein R<sup>1</sup> is 3-(tert-butoxycarbonylamino)pyrazol-5-yl, 3-(amino)pyrazol-5-yl, 3-(acetamido)pyrazol-5-yl, 3-(propionamido)pyrazol-5-yl, 3-(*iso*-propylcarbonylamino)pyrazol-5-yl, furan-2-yl, 4-(ethoxycarbonyl)-5-methylimidazol-1-yl, 5-(bromo)imidazol-1-yl, 5-methyl-1,3,4-triazol-2-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 3-ethoxycarbonyl-1,2,4-oxadiazol-5-yl, 4-(carboxy)furan-2-yl, 2,4-dimethylthiazol-5-yl, 3-(tert-butyl)isoxazol-5-yl, thiophen-2-yl, 3-methoxyisoxazol-5-yl, 4-methylthiazol-5-yl, 3,5-dimethylisoxazol-4-yl, isoxazol-3-yl, 3-methylisoxadiazol-4-yl, isoxathiazol-5-yl, 3-methylisoxazol-5-yl, 2-methylthiazol-4-yl, 5-(tert-butoxycarbonylhydrazinocarbonyl)furan-2-yl, 5-(hydrazinocarbonyl)furan-2-yl, 5-(3-methyl-1,2,4-oxadiazol-5-yl)furan-2-yl, 5-(2-methyl-1,2,4-triazol-5-yl)furan-2-yl, 3-amino-2-methyl-1,2,4-triazol-5-yl, 3-amino-1,2,4-triazol-5-yl, 3-amino-1,2,4-oxadiazol-5-yl, 4-(tert-butoxycarbonyl)pyrazol-1-yl, 2-(pyrazin-2-yl)thiazol-4-yl, 2-(methylaminocarbonyl)furan-5-yl, 2-(ethoxycarbonyl)furan-5-yl, 2-(ethylaminocarbonyl)furan-5-yl, 2-(*iso*-propylaminocarbonyl)furan-5-yl, 2-(cyclopropylaminocarbonyl)furan-5-yl, 2-(cyclopropylmethylaminocarbonyl)furan-5-yl, 2-(5-methyl-1,3,4-oxadiazol-2-yl)furan-2-yl, 3-(methylaminocarbonyl)-1,2,4-oxadiazol-5-yl, 3-(ethylaminocarbonyl)-1,2,4-oxadiazol-5-yl, 3-(*iso*-propylaminocarbonyl)-1,2,4-oxadiazol-5-yl, 2-chlorothiophen-4-yl, 3-aminoisoxazol-5-yl, 3-acetamidoisoxazol-5-yl, 3-propionamidoisoxazol-5-yl, 3-(*iso*-propylcarbonylamino)isoxazol-5-yl, 4-(ethoxycarbonyl)furan-2-yl, 5-(methoxycarbonyl)furan-2-yl, 4-(*iso*-propylaminocarbonyl)furan-2-yl, 4-(ethylaminocarbonyl)furan-2-yl, 4-(methylaminocarbonyl)furan-2-yl, 5-(ethylaminocarbonyl)furan-2-yl, 5-(methylaminocarbonyl)furan-2-yl, 5-(*iso*-propylaminocarbonyl)furan-2-yl, 4-(ethoxycarbonyl)furan-2-yl, pyridin-3-yl, furan-2-yl, 2-(5-methylisoxazol-3-yl)thiazol-4-yl, 2-(1-methylimidazol-5-yl)thiazol-4-yl, 2-(4-methyl-1,2,3-thiadiazol-5-yl)thiazol-4-yl, 5-methyl-2-(5-methylisoxazol-3-yl)thiazol-4-yl, 5-methyl-2-(1-methylimidazol-5-yl)thiazol-4-yl, 2-(4-methyl-1,2,3-thiadiazol-5-yl)-5-methylthiazol-4-yl, 2-(1-methylimidazol-5-yl)thiazol-4-yl, 4-methyl-2-(5-methylisoxazol-3-yl)thiazol-2-yl, 4-methyl-2-(5-methylisoxazol-5-yl)thiazol-5-yl, 3-(thiophen-2-yl)-4-(methyl)pyrazol-1-yl, 5-(*iso*-propyl)tetrazol-1-yl, 5-methyl-3-(trifluoromethyl)pyrazol-1-yl, 3-(thiazol-2-yl)pyrazol-1-yl, 5-(piperidin-1-yl)tetrazol-2-yl, 5-(piperidin-1-yl)tetrazol-1-yl, 1-(methyl)tetrazol-5-yl, tetrazol-5-yl, 5-(methyl)isoxazol-3-yl, 5-(*iso*-propyl)tetrazol-2-yl, 2-(methyl)tetrazol-5-yl, 3-(methyl)isoxazol-5-yl, 3-(formyl)pyrazol-1-yl, 3-(methyl)pyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, or 4-(ethoxycarbonyl)pyrazol-1-yl.

4. A compound of formula (I) according to any one of the preceding claims  
40 wherein R<sub>na</sub> and R<sub>nb</sub> are both hydrogen.

5. A compound of formula (I) according to any one of the preceding claims wherein n is 1 or 2.
- 5 6. A compound of formula (I) according to any one of the preceding claims wherein R<sup>3</sup> is hydrogen.
7. A compound of formula (I) according to any one of the preceding claims wherein R<sup>2</sup> is phenyl substituted with chloro or fluoro, or thiophenyl substituted  
10 with chloro.
8. A compound of formula (I) according to any one of the preceding claims wherein R<sup>2</sup> is 3-fluorophenyl, 3-(trifluoromethyl)phenyl, 2-chlorothiophen-4-yl, 3-chlorophenyl, 3,4-difluorophenyl or 3,4-dichlorophenyl.
- 15 9. A compound of formula (I) according to claim 1 selected from the Examples.
10. A compound of formula (I) according to claim 9 selected from Examples  
20 1, 2, 3, 8, 12, 14, 16, 18, 19, 20, 21, 23, 25, 27, 28, 30, 31, 32, 34, 36, 40, 42, 45, 46, 48, 49, 50, 52, 53, 54, 55, 56, 58, 60, 63, 64, 65, 67, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 80, 81, 82, 83, 87, 88, 89, 90, 91, 93, 95, 97, 99, 100, 102, 104, 106, 108, 109, 110, and 111.
- 25 11. A compound of formula (I) according to claim 9 selected from Examples 1, 2, 3, 19, 23, 27, 32, 34, 36, 42, 45, 48, 50, 52, 54, 58, 63, 64, 65, 67, 71, 75, 76, 78, 80, 89, 91, 93, 97, 102, 104, and 106.
12. A compound of formula (I) according to claim 9 selected from Examples  
30 1, 23, 32, 34, 36, 50, 71, 78, and 97.
13. A process for the preparation of a compound of formula (I) as defined in claim 1 which process comprises the reaction of a compound of formula (II) with a compound of formula (III);

35




wherein;

$R^1$ , Y,  $R^3$ , and  $R^2$  are as hereinbefore defined for formula (I) in claim 1 in the presence of an activating agent and a peptide coupling agent, and thereafter, if required, carrying out one or more of the following optional steps:


- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

10 14. A process for the preparation of a compound of formula (I) wherein Y is -CH<sub>2</sub>- and  $R^1$  is an unsubstituted or substituted N-linked heteroaryl group i.e. a compound of formula (XI)



15

which process comprises the reaction of a compound of formula (XII) with a compound of formula (XIII);




20

wherein (XII) is an unsubstituted or substituted heteroaryl group,  $L^2$  is a leaving group, and  $R^3$  and  $R^2$  are as hereinbefore defined for formula (I) in claim 1, and thereafter, if required, carrying out one or more of the following optional steps:


- (i) converting a compound of formula (I) to a further compound of formula (I);
- 25 (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

15. A compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.
16. A compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. asthma or rhinitis.
17. Use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.
18. A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition e.g. asthma or rhinitis, which method comprises administering an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.
19. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.
20. A compound of formula (IIIBR)




- 25 wherein A is a protected amino group and R<sup>2</sup> is as defined for formula (I) in claim 1.

21. A compound of formula (IIIBE).



wherein A is a protected amino group and  $R^2$  is as defined for formula (I) in claim 1.

22. A compound of formula (XIII).  
5



wherein  $L^2$  is a leaving group and  $R^3$  and  $R^4$  are as defined for formula (I) in claim 1.

10